Hepatitis B virus (HBV) DNA was extracted from sera of six carriers with hepatitis B e antigen as well as antibody to hepatitis B surface antigen and sequenced within the pre-S regions and the S gene. HBV DNA clones from five of these carriers had point mutations in the S gene, resulting in conversion from Thr-126 of the wild-type virus to in three carriers and conversion from Gly-145 to in three of them; clones with Asn-126 or Arg-145 were found in one carrier. All 12 clones from the other carrier had an insertion of 24 bp encoding an additional eight amino acids between Thr-123 and Cys-124. In addition, all or at least some of the HBV DNA clones from these carriers had in-phase deletions in the 5' terminus of the pre-S2 region. These results indicate that HBV escape mutants with mutations in the S gene affecting the expression of group-specific determinants would survive in some carriers after they seroconvert to antibody against surface antigen. Carriers with HBV escape mutants may transmit HBV either by donation of blood units without detectable surface antigen or through community-acquired infection, which would hardly be prevented by current hepatitis B immuneglobulin or vaccines.
Hepatitis B virus (HBV) DNA was extracted from sera of six carriers with hepatitis B e antigen as well as antibody to hepatitis B surface antigen and sequenced within the pre-S regions and the S gene. HBV DNA clones from five of these carriers had point mutations in the S gene, resulting in conversion from Thr-126 of the wild-type virus to Ser-126 or Asn-126 in three carriers and conversion from Gly-145 to in three of them; clones with Asn-126 or Arg-145 were found in one carrier. All 12 clones from the other carrier had an insertion of 24 bp encoding an additional eight amino acids between Thr-123 and Cys-124. In addition, all or at least some of the HBV DNA clones from these carriers had in-phase deletions in the 5' terminus of the pre-S2 region. These results indicate that HBV escape mutants with mutations in the S gene affecting the expression of group-specific determinants would survive in some carriers after they seroconvert to antibody against surface antigen. Carriers with HBV escape mutants may transmit HBV either by donation of blood units without detectable surface antigen or through community-acquired infection, which would hardly be prevented by current hepatitis B immuneglobulin or vaccines.
The envelope gene of hepatitis B virus (HBV) codes for three kinds of proteins, which are translated from distinct mRNA (for a review, see reference 30) and collectively called hepatitis B surface antigen (HBsAg). The major HBsAg is coded for by the S gene and made up of 226 amino acids (aa). The middle HBsAg is coded for by the pre-S2 region (55 aa) and the S gene, while the large HBsAg is coded for by the pre-Sl region (119 or 108 aa, depending on subtypes), the pre-S2 region, and the S gene.
Escape mutants of HBV which have point mutations in the S gene resulting in amino acid changes for the loss of the group-specific determinant called a have been reported. They arise in persons infected with HBV after they receive hepatitis B vaccine (3, 5, 7, 19) or in patients with orthotopic liver transplantation on therapeutic trials with monoclonal antibody to HBsAg (anti-HBs) (11) . HBV escape mutants are reported, also, in a carrier who did not receive hepatitis B immuneglobulin or vaccine (12) . HBV mutants with deletions in the pre-S2 region occur in persons persistently infected with HBV and replace wild-type HBV (6, 23) . HBV mutants with mutations in the pre-S2 region or the S gene would arise in the natural course of HBV infection, instigated by the selective pressure of immune responses of hosts for the survival of the fittest.
Six individuals with persistent HBV infection who had hepatitis B e antigen (HBeAg) in sera, despite the fact that they tested positive for anti-HBs, were identified. HBV DNA clones were propagated from their sera, and sequences of the pre-S regions and the S gene were determined. Patterns of deletions in the pre-S2 region and point mutations in the S MATERIALS AND METHODS Serum samples. Sera which contained HBeAg and hightitered antibody to hepatitis B core antigen (anti-HBc) in spite of positivity for anti-HBs were selected. They were from an asymptomatic carrier of HBV (case 1), a patient with liver cirrhosis (case 2), a patient with primary hepatocellular carcinoma (case 3), and three patients with chronic hepatitis B (cases 4 to 6). The case 1 carrier was tested at three time points during 11 years, the last serum sample being taken after he had seroconverted to antibody to HBeAg (anti-HBe). Serological profiles of the six carriers are shown in Table 1 .
Additionally studied were 14 HBV carriers with conventional serologies. Nine of them had HBsAg and HBeAg, while the remaining five possessed HBsAg and were seropositive for anti-HBe. They all had high-titered anti-HBc.
Serological assays. HBsAg and anti-HBs were determined by enzyme immunoassay (EIA) with commercial kits (AUSZYME II and AUSAB; Abbott Laboratories, Abbott Park, Ill.) with cutoff A492 values of 0.14 and 0.21, respectively. These assays involved the group-specific determinant of HBsAg called a that is maintained by conformation of two loop structures constructed by aa 124 to 147 of the product of the S gene (1, 3) . Anti-HBc was determined in sera diluted 1:200 with EIA kits (Corzyme; Abbott). HBeAg and anti-HBe were determined by EIA with commercial kits (HBeAg/Ab EIA;
Institute of Immunology Co., Ltd., Tokyo, Japan).
Antigenicity of the pre-S2 region product was determined by a sandwich EIA with horse polyclonal anti-HBs immobilized 2672 YAMAMOTO ET AL. Cloning and sequencing of the pre-S regions and the S gene. The pre-S regions and the S gene were amplified on HBV DNA extracted from 25 p1I of serum by PCR with AmpliTaq DNA polymerase (Perkin-Elmer Cetus, Norwalk, Conn.) and nested primers. The entire sequence of the pre-S regions and the S gene was amplified by two separate PCR procedures, the products of which overlapped within nucleotides (nt) 64 to 137 in the pre-S2 region; nucleotides were numbered from the unique EcoRI site of the HBV genome.
The first round of PCR for the amplification of the pre-Sl region and a part of the pre-S2 region was performed with 5 The product of PCR was treated with T4 DNA polymerase (Takara Biochemicals, Kyoto, Japan) and T4 polynucleotide kinase (New England Biolabs Inc., Beverly, Mass.) and inserted into the M13 phage vector. Nucleotide sequences of amplified HBV sequences were determined for both strands with the Sequenase DNA sequencing kit (7-deaza-dGTP edition version 2.0, United States Biochemical Corp., Cleveland, Ohio) or the AutoRead DNA sequencing kit (Pharmacia LKB Biotechnology, Uppsala, Sweden).
Cloning and sequencing of the pre-C region. Cloning and sequencing of the pre-C region were performed by the method described previously (20) . Table 1 shows serological profiles of the six carriers with HBV DNA and HBeAg as well as high-titered anti-HBc in sera despite coexisting anti-HBs. Sera from the case 1 carrier were tested at three time points during 11 years, the last serum sample being taken after he had seroconverted to anti-HBe; HBsAg and anti-HBs co-occurred in all three serum samples. The antigenic activity for the pre-S2 region product was not detected in sera from any carriers. Antibody to pre-S2 antigen was detected in them all and in high titers in three of them.
RESULTS
HBV DNA clones were propagated from serum samples from the six carriers, and sequences of the pre-S region and the S gene were determined ( Table 2 ). All or at least some of the HBV DNA clones from them possessed deletions in the pre-S2 region ( Fig. 1 Table 2 , from each carrier of cases 1, 3, 4, 5, and 6. Five different patterns of deletions were detected in 10 clones from the case 2 carrier; pattern a was detected in 6 clones and patterns b to e were detected in one clone each. The pre-C region was sequenced on more than 10 HBV DNA clones each from the six carriers. The G-to-A point mutation converting Trp-28 to a stop codon (2, 20) was detected in all 10 clones from the serum taken from the case 1 carrier after he seroconverted to anti-HBe and in 3 of 10 clones from the case 4 carrier. This mutation was not detected, however, in any of 20 HBV DNA clones from two serum samples from the case 1 carrier taken while he was positive for HBeAg or in any of 52 clones from the other carriers. None of the sequenced clones had any other mutations aborting the translation of the precursor of HBeAg.
Mutations in the pre-S regions and the S gene were searched for in HBV DNA clones propagated from 14 HBsAg carriers with conventional serologies (Table 3 ). Nine of them had HBeAg, while the remaining five were positive for anti-HBe. Various deletion mutations were detected in the pre-SI region of some HBV DNA clones from three carriers with HBeAg and two with anti-HBe. Deletions in the pre-S2 region were detected in some HBV DNA clones from three of the five carriers with anti-HBe; they were not detected in any clones from carriers with HBeAg. None of 42 HBV DNA clones from the 14 carriers had mutations at codon 126 or 145 in the S gene.
DISCUSSION
Hosts infected with HBV mount antibody responses of three different categories to viral antigens (8) . First, they raise antibodies to the viral nucleocapsid commonly called hepatitis B core antigen (HBcAg). Then, antibody is elicited to HBeAg, which is a secretory form of nucleocapsid protein produced by a distinct biosynthetic pathway (10, 31) and associated with active replication of HBV (15) . Last, hosts raise anti-HBs for the termination of HBV infection. Although anti-HBc does not interfere with viral replication, occurring in high titers in persistently infected hosts, anti-HBe and anti-HBs responses have crucial significance in the life cycle of HBV. They would be responsible for mutants with various mutations to evade immune surveillance occurring in persistently infected hosts.
Best known are HBV mutants with mutations in the pre-C region for aborting the secretion of HBeAg. The G-to-A point mutation at nt 1896, converting codon 28 of the pre-C region from T£G for Trp to TAG for a stop codon, is most frequently observed (2, 20) . These mutants prevail as the host seroconverts to anti-HBe, because hepatocytes infected with wild-type HBV and surface expression of HBeAg are selectively eliminated.
Although not frequent, mutants with mutations in the S gene affecting the expression of group-specific determinants of HBsAg are reported. The potent B-cell epitope of HBsAg is borne by aa 124 to 147 of the S gene product, which, it is proposed, make two loop structures maintained by a disulfide bond between Cys-124 and Cys-137 as well as between Cys-139 and Cys-147 (1, 3) . Point mutations converting Gly-145 to Arg-145, or Ile (Thr)-126 to Asn-126, abolish the expression of group-specific HBsAg determinants; mutants with these mutations can escape the vaccination or therapeutically administered monoclonal anti-HBs and prevail in circulation (3, 5, 7, 11, 19) .
HBV mutants with mutations in the envelope gene were searched for in sera from six carriers who had HBeAg in serum despite the fact that they were positive for anti-HBs. Various mutations affecting the expression of the pre-S2 region product and the S gene product were detected. Their analyses, taken along with similar mutations in previous reports, would help outline the pattern of mutations in the HBV genome for evolution in persistently infected hosts.
The G-to-A point mutation at nt 587 converting Gly-145 to Arg-145 was detected in three carriers. On the basis of this fact taken together with five previous reports describing this mutation in eight carriers (3, 5, 7, 11, 19) , nt 587 seems to be the hottest spot for an escape mutation to occur. Also notable were conversions of codon 126 in the S gene, which encodes either Ile or Thr in the wild-type HBV regulating allelic subtypic determinants of HBsAg called i and t (14) . Ser-126 was found in all 18 HBV DNA clones from the case 1 carrier, while Asn-126 was detected in all 10 clones from the case 6 carrier as well as in 4 of 11 clones from the case 5 carrier. Ser-126 has been reported in HBV DNA clones from a 66-year-old Japanese man with chronic hepatitis who was positive for HBeAg and anti-HBs (12), and Asn-126 has been reported in a baby who was born to an HBeAg-positive carrier mother and who received combined passive and active immunization (19) . Since the S gene sequence of these clones, except for codon 145 or codon 126, was not different from that of wild-type HBV, these changes would be responsible for the loss of group-specific determinants of HBsAg in these five carriers. A change not documented previously was an insertion of eight amino acids between Thr-123 and Cys-124 in all 12 clones from one of the carriers. Such a mutation is reasonably presumed to affect the expression of a group-specific determinant maintained by aa 124 to 147 of the S gene product.
Escape mutants with mutations in the S gene would pose a substantial risk to the community, because current hepatitis B immuneglobulin and vaccines are not effective in preventing infection with them. Blood units containing such mutants are missed by routine screening for HBsAg and can transmit HBV infection to recipients. Since these mutants can replicate actively with potent anti-HBc responses in hosts, the exclusion of blood units with high-titered anti-HBc (9) is expected to be effective for preventing their transmission by transfusions.
Deletions in the pre-S2 region were observed in all or at least some HBV DNA clones from the six carriers studied. All of them occurred in the 5' terminus of the pre-S2 region, like those described in HBV DNA clones from carriers infected with escape mutants (12) or without them (6, 23) . All deletions in the pre-S2 region were in phase; the expression of large or middle-sized HBsAg species or the P gene product would not be affected, albeit the product would be a little shorter than the authentic products. The pre-S2 region is doubly coded, in a different reading frame, for the DNA polymerase reverse transcriptase (30) . It falls on the spacer-tether region of the P gene product, which is not essential for enzyme activity (22 Anti-pre-S2 was detected in sera from all six carriers, and this would have been responsible for the selection of mutants with pre-S2 deletions. Anti-pre-S2 develops early in persons with acute HBV infection (13) and is detected in some carriers with anti-HBe (18) . Anti-pre-S2 seroconversion seems to be linked, in some way, to anti-HBe seroconversion; HBsAg particles co-occurring with HBeAg in sera of carriers possess the pre-S2 region product in much higher quantities than those coexisting with anti-HBe (28) .
Deletions in the pre-S2 region were searched for in HBV DNA clones from 14 HBV carriers with conventional serologies, including nine with HBeAg and five with anti-HBe. Pre-S2 deletions were detected in some HBV DNA clones from three carriers with anti-HBe but not in any of 31 clones from nine carriers with HBeAg. Pre-S2 deletions in HBV DNA clones from the six carriers infected with escape mutants, therefore, would be unique in that they occurred despite coexisting HBeAg. It is not known whether pre-S2 deletions have any significance for the development of escape mutants. A similar pre-S2 deletion has been reported in an escape mutant (12) . It would be worthwhile to sequence the pre-S2 region in the other escape mutants to substantiate this association further and to evaluate any causal relationship between them.
HBV evolves rapidly for a DNA virus (16) , because its replication involves the reverse transcription of an RNA intermediate (27) , a process prone to errors due to the lack of proofreading enzymes (26) . Because of seroconversion to anti-HBe and anti-pre-S2 in hosts occurring earlier than anti-HBs responses, mutants with mutations in the pre-C and pre-S2 regions would commonly occur. Since, in general, the replication of HBV is virtually shut off after the host seroconverts to anti-HBe (15) , chances are slim for escape mutants with mutations in the S gene to appear in circulation. In rare carriers such as those described here and reported previously (12) , however, anti-HBs seroconversion may occur before anti-HBe seroconversion, for some reason or other, and escape mutants would arise in them naturally.
Given the evidence for versatility of the HBV genome in the evasion of various immune pressures of the host, it is not very hard to imagine mutations in the C gene to deprive core particles of immunogenicity for HBcAg. This view would be supported by the failure of chimeric HBV core particles assembled by hybrid core proteins with an insertion of 27 aa between positions 75 and 83 to bind with anti-HBc (25) . Indeed, HBV might eventuate in a cyborg mutant that does not stimulate anti-HBe, anti-pre-S2, anti-HBs, or even anti-HBc responses in the host, accounting for the mystery of HBV DNA sequences in sera and hepatocytes of patients without any serological markers of HBV infection (21, 29 
